tetano
Editor, Senior Moderator
Virol J
. 2023 Oct 16;20(1):236.
doi: 10.1186/s12985-023-02191-z. Prevalence, clinical significance, and persistence of autoantibodies in COVID-19
Se Ju Lee[SUP] #[/SUP][SUP] 1 2 [/SUP], Taejun Yoon[SUP] #[/SUP][SUP] 3 [/SUP], Jang Woo Ha[SUP] 4 [/SUP], Jinnam Kim[SUP] 1 [/SUP], Ki Hyun Lee[SUP] 1 [/SUP], Jung Ah Lee[SUP] 1 [/SUP], Chang Hyup Kim[SUP] 1 [/SUP], Sang-Won Lee[SUP] 4 [/SUP], Jung Ho Kim[SUP] 1 [/SUP], Jin Young Ahn[SUP] 1 [/SUP], Nam Su Ku[SUP] 1 [/SUP], Jun Yong Choi[SUP] 1 [/SUP], Joon-Sup Yeom[SUP] 1 [/SUP], Su Jin Jeong[SUP] 5 [/SUP]
Affiliations
Background: Interest in complications and sequelae following Coronavirus disease 2019 (COVID-19) is increasing. Several articles have reported COVID-19-associated autoimmune diseases and the association between autoantibodies and the severity of COVID-19. Thromboembolic complications are frequent in patients with COVID-19, and the anti-phospholipid antibodies (aPL) is frequently detected. We conducted this study to investigate the prevalence, clinical significance, and persistence of anti-nuclear antibodies (ANA) and aPLs in COVID-19.
Methods: We enrolled patients diagnosed with COVID-19 with oxygen demand and admitted to a tertiary hospital in South Korea between July 2020 and March 2022. ANA and aPLs levels were assessed using an immunoassay kit.
Results: A total of 248 patients were enrolled in the study. Among them, five patients were ANA-positive, and 41 were aPL-positive (IgM anti-cardiolipin (aCL) antibody in seven patients, IgG aCL in seven patients, IgM anti-β2Glycoprotein1 antibody (aβ2-GPI) in 32 patients, and IgG aβ2-GPI in one patient). Two of five ANA-positive patients, 13 of 32 IgM aβ2-GPI-positive patients, 5 of 7 IgM aCL-positive patients, and 2 of 7 IgG aCL-positive patients were eligible for follow-up analysis, and 100%, 69.2%, 40%, and 50% of the patients remained autoantibody-positive, respectively. There were no differences in clinical outcomes between the autoantibody-positive and autoantibody-negative groups, except for the IgG aCL group showing a tendency for worse outcomes.
Conclusion: A significant proportion of COVID-19 patients with oxygen demand were autoantibody-positive, and autoantibodies persisted for several months after symptom onset. Whether these autoantibodies are related to long-term sequelae in COVID-19 patients requires further investigation.
Keywords: Anti-nuclear antibody; Anti-phospholipid antibody; Autoantibody; COVID-19.
. 2023 Oct 16;20(1):236.
doi: 10.1186/s12985-023-02191-z. Prevalence, clinical significance, and persistence of autoantibodies in COVID-19
Se Ju Lee[SUP] #[/SUP][SUP] 1 2 [/SUP], Taejun Yoon[SUP] #[/SUP][SUP] 3 [/SUP], Jang Woo Ha[SUP] 4 [/SUP], Jinnam Kim[SUP] 1 [/SUP], Ki Hyun Lee[SUP] 1 [/SUP], Jung Ah Lee[SUP] 1 [/SUP], Chang Hyup Kim[SUP] 1 [/SUP], Sang-Won Lee[SUP] 4 [/SUP], Jung Ho Kim[SUP] 1 [/SUP], Jin Young Ahn[SUP] 1 [/SUP], Nam Su Ku[SUP] 1 [/SUP], Jun Yong Choi[SUP] 1 [/SUP], Joon-Sup Yeom[SUP] 1 [/SUP], Su Jin Jeong[SUP] 5 [/SUP]
Affiliations
- PMID: 37845706
- DOI: 10.1186/s12985-023-02191-z
Background: Interest in complications and sequelae following Coronavirus disease 2019 (COVID-19) is increasing. Several articles have reported COVID-19-associated autoimmune diseases and the association between autoantibodies and the severity of COVID-19. Thromboembolic complications are frequent in patients with COVID-19, and the anti-phospholipid antibodies (aPL) is frequently detected. We conducted this study to investigate the prevalence, clinical significance, and persistence of anti-nuclear antibodies (ANA) and aPLs in COVID-19.
Methods: We enrolled patients diagnosed with COVID-19 with oxygen demand and admitted to a tertiary hospital in South Korea between July 2020 and March 2022. ANA and aPLs levels were assessed using an immunoassay kit.
Results: A total of 248 patients were enrolled in the study. Among them, five patients were ANA-positive, and 41 were aPL-positive (IgM anti-cardiolipin (aCL) antibody in seven patients, IgG aCL in seven patients, IgM anti-β2Glycoprotein1 antibody (aβ2-GPI) in 32 patients, and IgG aβ2-GPI in one patient). Two of five ANA-positive patients, 13 of 32 IgM aβ2-GPI-positive patients, 5 of 7 IgM aCL-positive patients, and 2 of 7 IgG aCL-positive patients were eligible for follow-up analysis, and 100%, 69.2%, 40%, and 50% of the patients remained autoantibody-positive, respectively. There were no differences in clinical outcomes between the autoantibody-positive and autoantibody-negative groups, except for the IgG aCL group showing a tendency for worse outcomes.
Conclusion: A significant proportion of COVID-19 patients with oxygen demand were autoantibody-positive, and autoantibodies persisted for several months after symptom onset. Whether these autoantibodies are related to long-term sequelae in COVID-19 patients requires further investigation.
Keywords: Anti-nuclear antibody; Anti-phospholipid antibody; Autoantibody; COVID-19.